FDA approves daraxonrasib, the first RAS-targeted pill for metastatic pancreatic cancer

A long-awaited opening in a difficult cancer

The U.S. Food and Drug Administration has approved Rasonque, the brand name for daraxonrasib, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy [1]. The decision is striking not only because pancreatic cancer has had few transformative drug advances, but also because daraxonrasib is designed to attack RAS, a central cancer-driving pathway long considered one of oncology’s hardest targets [2].

The FDA described Rasonque as a once-daily tablet and a RAS inhibitor for the most common form of pancreatic cancer [1]. Dana-Farber Cancer Institute, whose investigators led the pivotal RASolute 302 trial, called daraxonrasib the first approved targeted therapy in pancreatic cancer designed to inhibit RAS [2]. That is the core significance of the approval: the drug is not simply another chemotherapy option, but a targeted oral therapy aimed at a molecular engine that helps many pancreatic tumors grow.

The approval covers metastatic pancreatic adenocarcinoma, not all pancreatic cancer and not earlier-stage disease [1]. It applies after at least one prior systemic therapy, or for patients who cannot receive multiagent systemic therapy [1]. That distinction matters for patients and physicians because the decision establishes a new option in a defined setting rather than a blanket replacement for first-line treatment.

What the trial showed

The clinical basis for approval was RASolute 302, a randomized, open-label, multicenter phase 3 trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma [1]. Patients were assigned to receive either daraxonrasib or a physician’s choice of standard-of-care chemotherapy [3]. The main efficacy measures included overall survival and progression-free survival, assessed in both the overall study population and in patients with a RAS G12 mutation [3].

The survival result is the headline: median overall survival was 13.2 months with daraxonrasib compared with 6.7 months with standard chemotherapy [1]. Dana-Farber reported the same median overall survival figures and said daraxonrasib reduced the risk of death by 60 percent in the overall study population, with a hazard ratio of 0.40 [2]. The ASCO Post reported a statistically significant improvement in overall survival, with a hazard ratio of 0.40, a 95 percent confidence interval of 0.30 to 0.53, and a P value below.0001 [3].

The trial also showed improvement in disease control. Dana-Farber reported median progression-free survival of 7.2 months with daraxonrasib versus 3.6 months with chemotherapy [2]. The ASCO Post reported the same progression-free survival figures and a hazard ratio of 0.49, with a 95 percent confidence interval of 0.38 to 0.64 and a P value below.0001 [3]. Objective response rate was also higher with daraxonrasib, at 30 percent compared with 11 percent in the chemotherapy arm, according to The ASCO Post [3].

These numbers explain why the approval is being framed as a landmark. In the AP’s account, patients taking the drug nearly doubled their survival time and had fewer severe side effects in the study comparing the experimental treatment with additional chemotherapy [4]. STAT reported that the therapy, made by Revolution Medicines, nearly doubled overall survival in the pivotal trial and is expected to usher in a new era of treatment [5].

Why RAS matters

RAS proteins help regulate cell growth, and mutated RAS signaling can become a driver of cancer growth. The FDA said Rasonque targets multiple forms of RAS, a key driver of tumor growth in most patients with pancreatic adenocarcinoma [1]. Dana-Farber said more than 90 percent of patients with pancreatic cancer have cancer-driving mutations in KRAS, an oncogene within the RAS family [2].

For decades, that biology was both obvious and frustrating. The AP reported that KRAS mutations are especially important in pancreatic cancer, but the protein’s structure made it hard for drugs to attach, contributing to RAS being considered “undruggable” for years [4]. Daraxonrasib’s importance comes from changing that treatment story: it is designed to inhibit active RAS signaling rather than simply treat the cancer with broadly cytotoxic chemotherapy.

Dana-Farber described daraxonrasib as an oral multi-selective RAS(ON) inhibitor and said it works as a “molecular glue” that, together with cyclophilin A, blocks RAS protein signaling [2]. In practical terms, the drug is intended to interfere with a common upstream driver across pancreatic tumors rather than pursue only one narrow downstream consequence of that driver.

Who may receive the drug now

The FDA indication is specific: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy [1]. The recommended dose reported by The ASCO Post is 300 mg orally once daily until disease progression or unacceptable toxicity [3].

The approval therefore gives oncologists a new second-line or later-line option and a possible route for patients who cannot tolerate intensive combination chemotherapy. It does not mean every pancreatic cancer patient should immediately receive daraxonrasib, and it does not remove the need for individual treatment planning. Tumor type, prior therapy, performance status, organ function, side-effect risks, insurance coverage, and clinician judgment will all shape how the drug is used.

The FDA granted the approval to Revolution Medicines [1]. STAT reported that daraxonrasib will be sold under the brand name Rasonque and described it as a medicine made by Revolution Medicines that is the first to attack a genetic cause of the aggressive malignancy [5]. ABC News also reported that the drug will be sold as Rasonque by Revolution Medicines [6].

Speed, designations and regulatory pathway

The FDA said the approval was granted 6.5 months before the user fee deadline [1]. The agency also said Rasonque had Breakthrough Therapy and Orphan Drug designations, received Priority Review for this indication, and was reviewed under the Commissioner’s National Priority Voucher pilot program [1]. The ASCO Post reported that the review used Project Orbis, with FDA collaboration with Health Canada and observer roles for the European Medicines Agency and Japan’s Pharmaceuticals and Medical Devices Agency [3].

That speed is unusual and reflects the combination of clinical need and trial effect size. The FDA had also allowed expanded access before approval, issuing a “safe to proceed” letter in May so the sponsor could initiate a treatment protocol for eligible patients before the medicine was formally approved [1]. AP reported that public interest increased earlier this year after former Senator Ben Sasse discussed taking the drug and experiencing less pain, helping draw attention to the expanded-access pathway [4].

The accelerated timing should not be confused with uncertainty about whether the approval is real. This is an FDA approval for a defined indication, supported by a randomized phase 3 trial [1]. At the same time, it remains the beginning of a new clinical chapter rather than the end of the research story.

Safety and limits

Daraxonrasib is not a cure. AP quoted Dr. Pashtoon Kasi of City of Hope Orange County as saying it is “one more option” and the best option the field has had for these patients [4]. That framing is important: a median survival improvement is meaningful for a disease with poor outcomes, but some patients will not respond, some will progress, and some may stop treatment because of toxicity.

The FDA listed the most common side effects as rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage [1]. The ASCO Post reported that the prescribing information includes warnings and precautions for dermatologic and soft tissue toxicity, stomatitis and oral disorders, diarrhea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and embryo-fetal toxicity [3]. Dana-Farber said no new safety signals were observed compared with an earlier phase 1/2 report, and identified rash, mouth inflammation, nausea and diarrhea among the most common side effects [2].

For patients, the appeal of a once-daily oral drug should be balanced against monitoring needs. A pill can be easier to administer than infusion chemotherapy, but oral targeted therapy still requires careful toxicity management, dose decisions, drug-interaction review, and prompt reporting of symptoms such as severe diarrhea, breathing problems, fever, bleeding, or worsening abdominal pain.

Why this changes the field

Pancreatic adenocarcinoma is both common within pancreatic cancer and disproportionately deadly. The FDA said approximately 90 to 95 percent of the 67,000 new pancreatic cancer cases diagnosed each year in the United States are pancreatic adenocarcinoma [1]. The agency also said pancreatic adenocarcinoma represents about 3.2 percent of all cancer diagnoses but accounts for a disproportionately high share of cancer deaths because it is often detected late, progresses aggressively, and has historically had limited treatment options [1].

Dana-Farber reported that about 80 percent of patients are diagnosed after the cancer has invaded nearby tissues or spread to other parts of the body, when treatment options are more limited [2]. ABC News similarly reported that pancreatic adenocarcinoma’s high death toll is tied to late detection, aggressive disease course and historically limited treatment options [6].

The approval also changes the benchmark for future trials. New drugs in this setting will increasingly be judged against Rasonque, against combinations containing Rasonque, or against biological strategies that build on RAS inhibition. The ASCO Post quoted trial investigator Brian Wolpin as saying daraxonrasib is well positioned to become a new standard of care for adults with metastatic pancreatic cancer after prior systemic therapy or when multiagent systemic therapy is not appropriate [3].

The next question: access

The immediate issue now shifts from approval to access. Patients and oncologists will need clarity on commercial availability, insurance coverage, prior authorization, molecular testing practices, management of patients who had been receiving the drug through expanded access, and integration into treatment guidelines. The FDA approval is the regulatory doorway; real-world uptake depends on the health system moving quickly enough for patients with a fast-moving disease.

Still, the central medical message is clear. For a disease in which progress has often been incremental, daraxonrasib offers a targeted, oral, RAS-directed therapy with randomized evidence of improved survival, progression-free survival, and response compared with standard chemotherapy [1]. It is not the final answer to metastatic pancreatic cancer, but it is a new platform on which the next generation of treatment may be built.

Sources from the last 72 hours

1. [1]FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic CancerAug 26, 2026, 12:00 AM UTC
2. [2]FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-FarberAug 26, 2026, 12:00 AM UTC
3. [3]FDA Approves Daraxonrasib for Metastatic Pancreatic AdenocarcinomaAug 26, 2026, 2:02 PM UTC
4. [4]FDA approves new pancreatic cancer drug expected to usher in new era of treatmentAug 26, 2026, 12:00 AM UTC
5. [5]FDA approves breakthrough drug to treat advanced pancreatic cancerAug 26, 2026, 12:49 PM UTC
6. [6]FDA approves landmark pancreatic cancer drug that’s shown to improve survivalAug 26, 2026, 3:58 PM UTC

AI-generated article based on recent web research, then preserved as a dated editorial snapshot.